← Back to all signals
AMGN · Q3 2026

AMGEN INC

Reported 2026-08-04
BEAT
31EarnIQ signal
↗

Confidence rising

Moderate quarter-over-quarter shift

Amgen delivered robust revenue growth and strong volume expansion across key growth drivers despite biosimilar headwinds.

  • ✓Guidance was none, with low specificity.
  • ✓Management tone registered as confident (85/100).
  • ✓EarnIQ detected 0 potential management deflections.
Headline–confidence gap

Headline confirmed

Management confidence reinforces the reported beat.

EPS: reported vs expected+9.8%$6.29 vs $5.73
Revenue: reported vs expected+4.6%$10.1B vs $9.6B
Guidance specificityLowChange not comparable
Market expectations supplied by Finnhub · Reported vs consensus estimate

Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales.

✦
EarnIQ Premium

Understand exactly why confidence changed.

Unlock management-language evidence, guidance specificity, the pressure point, narrative breaks, risks, and quarter-over-quarter topic changes.

Guidance specificityPressure pointNarrative breakSource evidence
Preview full report